The Journal of Clinical Endocrinology & Metabolism · 2012 · 157 citations · 30 references
MedicineNuclear MedicineRadiologyCancer ScreeningDiagnostic ImagingDiagnostic RadiologyCancer DetectionPheochromocytoma ImagingTumor DetectionTumor ImagingContrast-enhanced Magnetic Resonance AngiographyIodine-123 Metaiodobenzylguanidine ScintigraphyLikelihood RatiosMagnetic Resonance AngiographyPheochromocytoma DetectionPheochromocytoma DiagnosisSomatostatin Receptor PetSomatostatin Receptor Scintigraphy
CONTEXT: Recommendations have not been established concerning imaging to screen SDHx mutation carriers for paraganglioma and pheochromocytoma. OBJECTIVE: Our objective was to compare the performance of gadolinium-enhanced magnetic resonance angiography, contrast-enhanced computed tomography, and [(123)I]metaiodo-benzylguanidine and somatostatin receptor scintigraphies for detecting head and neck and thoracic-abdominal-pelvic paragangliomas in SDHx mutation carriers. DESIGN AND SETTING: We conducted a prospective, multicenter study from June 2005 to December 2009 at 23 French medical centers. PATIENTS: A total of 238 index cases or relatives carrying mutations in SDHD, SDHB, or SDHC genes were included. INTERVENTION: Images obtained by each technique were analyzed blind, without knowledge of results from other tests, first in each local center and then centrally. MAIN OUTCOME MEASURES: We evaluated sensitivity, specificity, and likelihood ratios for individual and combinations of tests, the gold standard being the consensus of an expert committee. RESULTS: Two hundred two tumors were diagnosed in 96 subjects. At local assessment, the sensitivity of anatomical imaging for detecting all tumors was higher (85.7%) than that of both scintigraphic techniques (42.7% for [(123)I]metaiodo-benzylguanidine and 69.5% for somatostatin receptor scintigraphy), except for thoracic localizations where somatostatin receptor scintigraphy was more sensitive (61.5 vs. 46.2% for anatomical imaging and 30.8% for [(123)I]metaiodo-benzylguanidine scintigraphy). The best diagnostic performance during local assessment was obtained by combining anatomical imaging tests and somatostatin receptor scintigraphy (sensitivity 91.7%). Central assessment significantly increased the sensitivity (98.6%) of tests in combination. CONCLUSIONS: In routine practice, the imaging work-up for screening SDHx mutation carriers should include thoraco-abdomino-pelvic computed tomography, head and neck magnetic angiography, and somatostatin receptor scintigraphy. Expert centralized image assessment is recommended.
30
Dewi Astuti, Farida Latif, Ashraf Dallol et al. · The American Journal of Human Genetics · 2001 · 1.1K citations · Full text
Genetic Testing in Pheochromocytoma or Functional Paraganglioma
Laurence Amar, Jérôme Bertherat, Éric Baudin et al. · Journal of Clinical Oncology · 2005 · 680 citations · Full text
SDHA is a tumor suppressor gene causing paraganglioma
Nelly Burnichon, Jean-Jacques Brière, Rossella Libé et al. · Human Molecular Genetics · 2010 · 651 citations · Full text